Sun Pharmaceuticals Pvt. Ltd.

About

Fourth-largest specialized generic pharmaceutical firm in the world is Sun Pharmaceutical Industries Ltd. (Sun Pharma). More than 100 nations throughout the world rely on us to supply them with high-quality, reasonably priced medications that are also trusted by patients and medical professionals. An international pharmaceutical firm with its headquarters in Mumbai is Sun Pharmaceutical Industries Limited. Among other therapeutic areas, Neuro-Psychiatry (16%), Gastroenterology (13%), Anti-Infectives (10%), Diabetology (8%), and Pain/Analgesics (7%) are the main therapeutic areas that significantly contribute to the company’s revenue and market share.

History

In 1983, Dilip Shanghvi established Sun Pharmaceuticals in Vapi, Gujarat, with five psychiatric medication products. Products for cardiology and gastrointestinal were introduced in 1987 and 1989, respectively. Sun Pharma became the biggest pharmaceutical firm in India, the biggest Indian pharmaceutical company in the US, and the fourth-largest specialty generic company in the world after purchasing Ranbaxy in 2014.

The United States and other markets outside of India account for more than 72% of Sun Pharma’s sales. The company’s biggest market, the US, generates around 30% of its revenue; overall, formulations, or completed dosage forms, account for 93% of the company’s revenue. 44 locations worldwide, including those in Europe, Asia, Africa, Australia, and the US, are used for manufacturing.

In 2022, A license deal is reached between Sun Pharma and SPARC to market phenobarbital for injection in the US. Japan has been added to the license and supply agreements for WINLEVI by Sun Pharma and Cosmo. -Sun Pharma introduces CEQUA, the first dry eye medication in Canada to use nano micellar (NCELL) technology. -Under a sole patent licence from Lundbeck, Sun Pharma will launch its brand of Vortioxetine in India. -Sun Pharma purchases Fiterman Pharma’s Uractiv portfolio in Romania.

Famous Product